There’s a little more hope on the horizon! The Pfizer COVID-19 vaccine candidate is now being reported as 95% effective and the company producing it says it has no serious side effects.

Sharing an update on November 18, pharmaceutical company Pfizer confirmed that their potential vaccine continues to show positive signs.

Final analysis from clinical trials has found the candidate to be 95% effective against COVID-19, beginning 28 days after the first dose.

This efficacy was reportedly “consistent across age, gender, race and ethnicity demographics.”

Editor's Choice: Ontario Driver Literally Stops Caring & Goes 30 Years With Expired Plates


Effective against COVID-19

The update also revealed that efficacy in adults over 65 years old was over 94%, too.

In addition, Pfizer and BioNTech confirmed that no serious safety concerns were recorded during the vaccine’s Phase 3 trial.

Over 43,000 volunteers were involved in this phase of the study, half of whom received the dose and half received a placebo.

This comes a week after the company revealed the shot candidate was 90% effective in trial stages, a result Justin Trudeau described as “encouraging.”

Speaking on November 9, the PM confirmed that Canada had already secured “millions" of doses of Pfizer’s vaccine.

He said he hopes potential shots could arrive by early 2021.

Comments are now closed.
Account Settings
Share Feedback
Log Out

Register this device to receive push notifications